| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we examined genetic risk factors and noninvasive risk stratification of pulmonary hypertension in left heart failure. For genetic risk, we found that in left heart failure patients with pulmonary hypertension, those with genetic mutations associated with pulmonary hypertension had a worse prognosis than those without mutations.
For noninvasive risk stratification, we studied in heart failure hospitalized patients with preserved ejection fraction and showed that pulmonary hypertension with increased pulmonary vascular resistance is associated with death and heart failure hospitalization one year after discharge. Among the echocardiographic indices, left ventricular diameter of 48 mm or less and E/e'16.5 or greater were shown to be useful for risk stratification.
|
